Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls

Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls

The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared to healthy controls. 399 cancer patients and 90 healthy volunteers were enrolled. In the overall population, the incidence of VRAEs was significa...

Full description

Bibliographic Details
Main Authors: Nussara Pakvisal, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Nassamon Wanlapakorn, Ritthideach Yorsaeng, Yong Poovorawan, Piyapoom Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Suebpong Tanasanvimon, Passakorn Wanchaijiraboon
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
azd1222
chadox1-ncov-19
covid-19 vaccine
safety
adverse events
malignancy patients
cancer treatment
Online Access:http://dx.doi.org/10.1080/21645515.2022.2094149

Internet

http://dx.doi.org/10.1080/21645515.2022.2094149

Similar Items